KRAS gene mutation in colorectal cancer;Mutación del gen KRAS en el cáncer de colon y recto

Revista Medica de Chile

Volumn 141, Issue 9, 2013, Pages 1166-1172

  Roa, Iván ^a   Sánchez, Tamara ^b   Majlis, Alejandro ^b   Schalper, Kurt ^b  

^a Creative Bioscience Santiago   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Colonic neoplasms; Human; Rectal neoplasms; Sarcospan (Kras oncogene associated gene) protein

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CHILE; CODON; COLON TUMOR; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; RECTUM TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; CHILE; CODON; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTAL NEOPLASMS; YOUNG ADULT;

EID: 84893306514     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013000900009     Document Type: Article

References (46)

1. http://deis.minsal.cl/index.asp. 2012.
2. Zarate AJ, Alonso FT, Garmendia ML, López-Kostner F. Increasing crude and adjusted mortality rates for colorectal cancer in a developing South American country. Colorectal Dis 2013; 15 (1): 47-51.
3. Donoso A, Villarroel L, Pinedo G. [Increase in colon cancer mortality rates in Chile, during the period 1990-2003]. Rev Med Chile 2006; 134 (2): 152-8.
4. Bannura G, Contreras J, Cumsille MA, García C, Portalier P. [Results of the surgical treatment of colorectal cancer: analysis of recurrence and survival in 400 patients]. Rev Med Chile 1995; 123 (4): 464-72.
5. Bacolod MD, Barany F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 2011; 18 (13): 3694-700.
6. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
7. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69 (10): 4286-93.
8. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, et al. Genetic progression and the waiting time to cancer PLoS Comput Biol 2007; 3 (11): e225.
9. Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004; 10 (12 Pt 1): 4015-21.
10. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008; 105 (11): 4283-8.
11. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010; 17 (4): 1168-76.
12. Dietel M, Jährens K, Laffert M, Hummel M, Blaker H, Múller BM, et al. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2013.
13. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154 (1): 37-49.
14. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20 (18 Suppl): 1S-13S.
15. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer-An example of personalised medicine in action. Cancer Treat Rev 2013.
16. Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, et al. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One 2012; 7 (7): e41347.
17. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27 (9): 1477-84.
18. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18 (8): 2257-68.
19. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 2010; 36 (7): 550-6.
20. Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007; 6 (10): 683-90.
21. Bellolio RF, Álvarez VK, De la Fuente LM, León GF, Fullerton M DA, Soto DG, et al. [Hereditary colorectal cancer: Molecular analysis of APC and MLH1 genes]. Rev Med Chile 2006; 134 (7): 841-8.
22. Torres VA, Tapia JC, Rodríguez DA, Lladser A, Arredondo C, Leyton L, et al. E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription. Mol Cell Biol 2007; 27 (21): 7703-17.
23. De la Fuente MK, Álvarez KP, Letelier AJ, Bellolio F, Acuña ML, León FS, et al. Mutational screening of the APC gene in Chilean families with familial adenomatous polyposis: nine novel truncating mutations. Dis Colon Rectum 2007; 50 (12): 2142-8.
24. Roa JC, Roa I, Melo A, Araya JC, Villaseca MA, Flores M, et al. [p 53 gene mutation in cancer of the colon and rectum]. Rev Med Chile 2000; 128 (9): 996-1004.
25. López-Kostner F. Gene symbol: APC. Disease: Adenomatous polyposis coli. Hum Genet 2008; 124 (3): 316.
26. Roa SJC, García MP, Melo AA, Tapia EO, Villaseca HM, Araya O JC, et al. [Gene methylation patterns in digestive tumors]. Rev Med Chile 2008; 136 (4): 451-8.
27. Aravena T, Passalacqua C, Castillo Taucher S. [Molecular and genetic studies for hereditary colon cancer in two patients and their families]. Rev Med Chile 2010; 138 (12): 1530-4.
28. http://omim.org/entry/190070.
29. Levidou G, Saetta AA, Gigelou F, Karlou M, Papanastasiou P, Stamatelli A, et al. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World J Surg Oncol 2012; 10: 47.
30. Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S, et al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 2011; 10: 118.
31. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010: 150960.
32. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205 (12): 858-62.
33. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104 (6): 1020-6.
34. Liebvre A, Rouleau E, Buecher B, Mitry E. [Clinical significance of BRAF mutations in colorectal cancer]. Bull Cancer 2010; 97 (12): 1441-52.
35. Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012; 14 (11): 1023-31.
36. Woo J, Palmisiano N, Tester W, Leighton JC. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 2013; 119 (11): 1941-50.
37. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27 (35): 5924-30.
38. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFRtargeted therapy. Int J Cancer 2013 Feb 12. doi: 10.1002/ ijc.28106.
39. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26 (7): 823-33.
40. Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012; 38 (6): 618-25.
41. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, et al. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009; 21 (5): 1283-7.
42. Pérez-Ruiz E, Rueda A, Pereda T, Alcaide J, Bautista D, Rivas-Ruiz F, et al. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. Tumour Biol 2012; 33 (6): 1829-35.
43. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wildtype colorectal cancers. Clin Cancer Res 2012; 18 (17): 4753-63.
44. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011; 11 (6): 635-42.
45. Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A, et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 2010; 30 (10): 4229-35.
46. Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30 (10): 741-7.